(Q46099612)

19 December 2017

title

Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial (English)

1 reference

19 December 2017

Helicobacter pylori infectious disease

1 reference

1 reference

1 reference

Josip Bago

1

1 reference

19 December 2017

Branko Pevec

2

1 reference

19 December 2017

Monika Tomić

3

1 reference

19 December 2017

Marinko Marusić

4

1 reference

19 December 2017

Vinko Bakula

5

1 reference

19 December 2017

Petra Bago

6

1 reference

19 December 2017

publication date

1 January 2009

1 reference

19 December 2017

published in

Vienna Clinical Weekly

1 reference

19 December 2017

volume

121

1 reference

19 December 2017

issue

1-2

1 reference

19 December 2017

page(s)

47-52

1 reference

19 December 2017

https://scigraph.springernature.com/pub.10.1007/s00508-008-1122-2

exact match

0 references

cites work

Helicobacter pyloriInfection

1 reference

https://api.crossref.org/works/10.1007%2FS00508-008-1122-2

Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-008-1122-2

Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-008-1122-2

Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-008-1122-2

Antibiotic resistance in Helicobacter pylori: implications for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-008-1122-2

Clinical relevance of resistant strains of Helicobacter pylori: a review of current data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-008-1122-2

Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-008-1122-2

Review article: the treatment of refractory Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-008-1122-2

H pylori antibiotic resistance: prevalence, importance, and advances in testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-008-1122-2

A systematic review of Helicobacter pylori eradication therapy--the impact of antimicrobial resistance on eradication rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-008-1122-2

Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-008-1122-2

Second‐line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-008-1122-2

Real-time PCR assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-008-1122-2

Moxifloxacin: a review of its use in the management of bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-008-1122-2

Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-008-1122-2

Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-008-1122-2

High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-008-1122-2

Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-008-1122-2

Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-008-1122-2

Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-008-1122-2

Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-008-1122-2

Levofloxacin based regimens for the eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-008-1122-2

Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-008-1122-2

Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-008-1122-2

Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer

21 January 2018

1 reference

12 December 2020

Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients

1 reference

12 December 2020

Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of Helicobacter pylori in a developing country

1 reference

12 December 2020

Antibiotic resistance in Helicobacter pylori

1 reference

12 December 2020

Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study

1 reference

12 December 2020

Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection

1 reference

12 December 2020

Eradication of H. pylori in a developing country: comparison of lansoprazole versus omeprazole with norfloxacin, in a dual-therapy study

1 reference

12 December 2020

The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs. omeprazole-based one-week triple therapies in H. pylori eradication--a randomised controlled trial.

1 reference

12 December 2020

10.1007/S00508-008-1122-2

Identifiers

DOI

1 reference

19 December 2017

PubMed ID

19263014

1 reference

19 December 2017